Key facts
- This page summarizes Stephen Davis's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Aug 2024, 18:40.
Stephen Davis - 16 Aug 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- CEO, Director
- Issuer ticker
- ACAD
- Reported as of
- 16 Aug 2024
- Net transaction value
- -$485,094
- SEC form
- 4
- Accepted by SEC
- 20 Aug 2024, 18:40:42 UTC
- Prior SEC filing
- 03 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephen Davis filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 20 Aug 2024.
Change
- Previous filing in this sequence was filed on 03 May 2024.
- Current net transaction value: -$485,094.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACAD
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +17,333
- Change %
- +11%
- Price
- $0.000000
- Shares after
- 173,520
- Date
- 16 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ACAD
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +44,782
- Change %
- +26%
- Price
- $0.000000
- Shares after
- 218,302
- Date
- 16 Aug 2024
- Ownership
- Direct
- Footnotes
- F3
ACAD
transaction
Common Stock
Sale
- Transaction value
- $485,094
- Shares
- -31,747
- Change %
- -15%
- Price
- $15.28
- Shares after
- 186,555
- Date
- 19 Aug 2024
- Ownership
- Direct
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.
Footnote F2
Includes 956 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024.
Footnote F3
Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.
Footnote F4
The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.325, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.